摘要
目的:观察托伐普坦治疗恶性腹腔积液合并低钠血症患者后的血钠及24 h尿量等指标变化。方法:38例恶性腹腔积液合并低钠血症患者随机分为观察组和对照组,对照组给予常规利尿处理,观察组在常规治疗基础上联用托伐普坦片,治疗7 d后,比较两组患者治疗前后血钠、24 h尿量、腹围及体重等指标的变化,并观察治疗期间两组不良反应发生情况。结果:治疗后观察组的血钠水平较治疗前显著升高(P<0.01),治疗后两组24 h尿量均较治疗前增多(P<0.01),且治疗后观察组24 h尿量明显高于对照组(P<0.01)。观察组4例患者出现口干不适,两组间差异无统计学意义,治疗期间两组患者均未出现严重不良反应。结论:托伐普坦治疗恶性腹腔积液合并低钠血症患者的疗效确切,可以改善患者的生存质量,且安全可靠。
OBJECTIVE To study the efficacy and safety of tolvaptan against hyponatremia in patients with malignant ascites.METHODS Thirty eight advanced cancer patients with hyponatremia accompanied by ascites were randomly divided into study group and control group.Nineteen patients in control group received conventional diuretic regimen,while other 19 patients in study group received conventional diuretics plus tolvaptan.The efficacy and adverse events of tolvaptan were assessed after seven days of treatment.RESULTS Significant increase of serum sodium was found in study group at day 7（P〈0.05）.Moreover,24 hour urine volume in both group increased after treatment（P〈0.01）,but urine volume of the study group was remarkably more（P〈0.01）.The changes of the average body weight,abdominal circumference and edema of the tolvaptan group and control group were also improved but without significant difference（P〉0.05）.Dry mouth and thirst were the main adverse effects in the patients receiving tolvaptan or conventional diuretics,and only 4 cases（21.1%）of dry mouth were found in tovaptan group.There was no severe complication or adverse reaction.CONCLUSION Tolvaptan is a promising aquaretic for patients with hyponatremia accompanying malignant ascites,and it can improve quality of life with good safety and reliability.
出处
《中国医院药学杂志》
CAS
北大核心
2017年第5期443-446,共4页
Chinese Journal of Hospital Pharmacy
基金
国家自然科学基金(81202095)
高等学校博士学科点专项科研基金(20120142120053)
